Default object view. Click to create a custom template, Node ID: 208036, Object ID: 122320

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label,...

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

No relation

Yes

No relation

No

04/03/2017 8:49 am

Yes